Dr. Ken Spielvogel
speaker
624 appearances
2 recordings
1 series
first heard Mar 2025
last heard 20 Jan
Dr. Ken Spielvogel’s voice in public audio — every appearance, attributed to the second.
Trend
recordings per month · last 12 monthsRecordings per month over the last 12 months — 1 in all, peaking in Jan 2026 with 1.
Appearances
That's a great question.
I mean, I think that it's a...
It's a complex answer.
First of all, the Zepbound, which is terzepatide, is a GLP-GIP receptor agonist, where Ozempic, which is semaglutide, is just a GLP agonist.
Man, can you dumb that down for my audience?
Or how about dumbing it down for me?
So it works in two different places with terzepatide.
And semaglutide works in one place.
So two is better than one, if we really want to say it.
You're probably going to lose more weight.
You're probably going to have more appetite suppression.
On the Z-bound.
On Z-bound.
And you're going to have an increased sensation of being full sooner.
Right.
And then probably the...
uh crave addiction type behavior is you know is squashed let's talk about it wasn't it wasn't squashed with the ozempic i could smoke all i wanted with ozempic right on zep bound i'm literally about one-tenth of my smoking consumption
Because there's receptors.
And I'm not enjoying it.
I'm doing it as habit and holding on.
Showing 81–100 of 624 · page 5 of 32
← Previous
Next →